Celgene should be bought aggressively, says RW Baird


Baird would be aggressive buyer of Celgene on the open today following positive test results for baraxene+gemcitaine in use for metastatic pancreatic cancer. Baird believes consensus estimates will be raised to levels near their above Street estimates. Shares are Outperform rated with a$92 price target.

View Comments (0)